All In Biotech

Free tool

FAERS Monitor: Cibinqo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213871 or its brand name (Cibinqo, Abrocitinib). Reports on generic versions are filed under their own applications.

Reports

3,948

Serious

1,377

35% of reports

Hospitalization

412

Death reported

70

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective537
  • condition aggravated366
  • off label use323
  • pruritus247
  • therapeutic product effect incomplete208
  • rash184
  • dermatitis atopic179
  • nausea166
  • headache109
  • eczema95
  • acne89
  • fatigue83
  • dizziness69
  • erythema64
  • skin exfoliation62

Reports by year received

View as table
YearReports
20192
20202
202111
2022416
20231,084
20241,189
2025967
2026277

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,211 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitis atopicSignal17918.115.72,880
therapeutic product effect incompleteSignal20815.613.72,833
eczemaSignal959.77.9732
condition aggravatedSignal3666.45.81,692
acneSignal896.35.1389
skin exfoliationSignal623.93.1132
pruritusSignal2473.43.0429
rashSignal1842.22.0129
drug ineffectiveSignal5372.22.0361
off label use3232.01.8159
erythema641.71.316
nausea1661.11.02
headache1090.90.81
dizziness690.70.66
fatigue830.60.528

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.